AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00212771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: asenapine
Description: Flexible dose, 1-2 tablets sublingual two times per day (1 or 2 tablets in the morning and 1 or 2 tablets in the evening). Each tablet contains either 5 mg asenapine or matching placebo.
Study NCT00212771 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: olanzapine
Description: Flexible dose, 1-2 capsules oral once per day (in the morning). Each capsule contains 10 mg olanzapine or matching placebo.
Study NCT03392961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IN-105 (Insulin Tregopil)
Description: 15 mg strength tablets for oral use used at a dose of 30 mg
Study NCT03392961 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: Placebo tablet for oral use
Study NCT00058617 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Injection of EBV Specific CTLs
Description: Each patient will receive two injections, 14 days apart, according to the following dosing schedules:~Group One Day 0 2x10\^7 cells/m2 Day 14 2x10\^7 cells/m2~Group Two Day 0 2x10\^7 cells/m2 Day 14 1x10\^8 cells/m2~Group Three Day 0 1x10\^8 cells/m2 Day 14 2x 10\^8 cells/m2~If patients with active disease have stable disease or a partial response by the RECIST criteria at their 8 week or subsequent evaluations they are eligible to receive up to 6 additional doses of CTLs at monthly intervals-each of which will consist of the same cell number as their second injection. Patients will not be able to receive additional doses until the initial safety profile is completed at 6 weeks following the second infusion.
Study NCT04366466 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: suicide attempt patient using PEPS Program
Description: The research protocol consists of two phases separated by randomization.~A Hospital Phase common to both groups:~Day zero is the day of the suicide attempt for which the patient came to the hospital.~A post-hospital phase including the P.E.P.S. program for the intervention group and telephone reminders for the usual treatment group.
Study NCT04366466 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: suicide attempt patient using PEPS Program
Description: The research protocol consists of two phases separated by randomization.~A Hospital Phase common to both groups:~Day zero is the day of the suicide attempt for which the patient came to the hospital.~A post-hospital phase including the P.E.P.S. program for the intervention group and telephone reminders for the usual treatment group.
Study NCT02248337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colon preparation for colonoscopy
Description: Colon cleansing prior to perform colonoscopy
Study NCT02248337 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colon preparation for colonoscopy
Description: Colon cleansing prior to perform colonoscopy
Study NCT01373892 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bariatric surgery
Study NCT02332135 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: microwave ablation
Description: First, the investigators detect the iPTH levels of all the patients in the investigators' blood purification center. The patients whose iPTH are between 300pg/ml and 800pg/ml and who have parathyroid nodular or diffuse hyperplasia demonstrated on ultrasound imaging or radioisotope scan are chosen to involve in this study. Patients are divided into 2 groups at random, the control group and the microwave ablation group. In the microwave ablation group, patients will accept microwave ablation. Oral medicines, if needed, will be taken according to the the suggestions in K/DOQI guideline.
Study NCT02332135 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: active vitamin D
Description: The control group will be treated by active vitamin D and other general treatment,such as dietary phosphate restriction and phosphate binders,according to the suggestions in K/DOQI guideline.
Study NCT01835132 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gevokizumab
Description: Subcutaneous injection of 60 mg gevokizumab
Study NCT01684722 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: Vitamin D3 (cholecalciferol), 2000 IU per day.
Study NCT01684722 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3 fatty acids (fish oil)
Description: Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid \[EPA\] and 375 mg of docosahexaenoic acid \[DHA\]).
Study NCT01684722 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D placebo
Description: Vitamin D3 placebo
Study NCT01684722 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D placebo
Description: Vitamin D3 placebo
Study NCT01684722 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fish oil placebo
Description: Fish oil placebo
Study NCT01684722 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Fish oil placebo
Description: Fish oil placebo
Study NCT04379661 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online support Group
Description: 12 one-hour, once-weekly online support groups for people with Multiple Sclerosis to address anxiety related to the COVID-19 outbreak and its effects on them.
Study NCT03773094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guava leaves extract
Description: Natural product : The leaves of the guava tree are full of antioxidants, anti-inflammatory agents, antibacterials, and even tannins that can have significant health benefits, from treating stomach troubles to chronic diseases like cancer~•
Study NCT03773094 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine
Description: chemical agent used as a mouthwash against cariogenic bacteria. considered the gold standard
Study NCT03426319 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiovascular evaluation
Description: Cardiovascular evaluation includes anamnesis, physical examination, laboratory tests, analysis of endothelial function, 24h blood pressure profile, Holter ECG, echocardiography and cardiac MRI.
Study NCT03815357 — intervention group
Intervention type: OTHER
Intervention: Referral to Immunology
Description: Screening for primary immunodeficiency including splenic dysfunction
Study NCT03349918 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile Health Monitoring
Description: Use of mobile health application to monitor blood pressure and mood.
Study NCT06520436 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arthroscopic-Assisted Reduction
Description: The arthroscopic-assisted reduction was used as a one-stage operative treatment for all hips. In addition to that, Dega pelvic osteotomy and/or femoral shortening and varus derotation osteotomies were performed when necessary.
Study NCT03807882 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bilateral M-ECT
Description: Following acute treatment with bilateral ECT of 6 sessions over a period of two weeks, Bilateral M-ECT will be administered at a frequency of 1 session/week for one month, then 1 session / 2 weeks for 2 months and then 1 session/month for next 3 months.
Study NCT03807882 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clozapine
Description: Clozapine will be given in accordance with Maudsley guideline: 12.5 mg on the first day, followed by 12.5mg twice daily on the second day, followed by 25mg twice daily for next two days and then increment of 25mg every two days till the target dose of 250-400 mg per day in two divided doses as per tolerability of the patients
Study NCT03654898 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: VITAL Start: Video-based pre-ART counseling
Description: Patients in the experimental group will receive VITAL start pre-ARV counseling (approximately 27 minutes video followed by 10 minute guided Q \& A to reinforce key messages and provide an opening for individual counseling=approximately total 37 minutes). This will be delivered by study staff.
Study NCT03654898 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care
Description: Patients randomized to the control arm will receive the usual standard of care (SOC) pre ARV initiation education with the National ARV Educational Flipchart
Study NCT03094806 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acapella Vibratory PEP Therapy Device plus usual care
Description: The acapella® Vibratory PEP Therapy System (PEP-FV) device is a handheld device that operates in same principle as standard FV. Unlike standard FV, it is not gravity dependent. It comes in two different devices to accommodate for different flows rates of the patient. It has similar properties of a standard FV and may be better tolerated.
Study NCT03094806 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham Acapella Vibratory PEP Device plus usual care
Description: The Sham Acapella Vibratory PEP Device is the same as the Therapy Device, except the flutter valve has been removed from the device.
Study NCT03578276 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pred-Gati-Brom
Description: The combination drop therapy containing prednisolone acetate 1%, gatifloxacin 0.5%, and bromfenac 0.075%
Study NCT01098006 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blood withdrawal
Description: A single blood sample was to be taken from all subjects at the study visit. No study-related treatment was given to the study participants.
Study NCT01876173 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Decision Aid for an ICD (primary prevention, non-CRT)
Description: The intervention group will receive the PtDA, which provides a lay summary that outlines the facts, risks, benefits (including probabilities), specific to the option of an implantable defibrillator or the option of medical management to prepare them for consultation with the physician. Values are assessed to reveal which features of each option are important to patients.
Study NCT03845348 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TD03
Description: Shampoo TD 3 days
Study NCT03845348 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TD07
Description: Shampoo TD 7 days
Study NCT03845348 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketoconazole 2% Shampoo
Description: Ketoconazole 2% Shampoo
Study NCT02806180 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dual Operator Ultrasound Guided IV placement
Description: Second operator holds ultrasound probe.
Study NCT02806180 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single Operator Ultrasound Guided IV placement
Description: Single operator holds ultrasound probe and places IV.
Study NCT03046212 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation
Description: TENS: it was applied in the conventional mode, through four self-adhesive electrodes of size 5x9cm positioned about five centimeters from the edges of the surgical scar, with frequency of 100 Hz and pulse duration of 100μs, for 30 minutes. The intensity was adjusted according to the maximum tolerance of the patient and was it increased during the application time with their permission.
Study NCT03046212 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercises
Description: Active exercises of plantar flexion and dorsal flexion of the ankles, flexion and extension of the knees and adduction and abduction of the hips, in both lower limbs. All exercises were performed with the patient in the supine position in the bed, in 10 repetitions.
Study NCT03046212 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercises
Description: Active exercises of plantar flexion and dorsal flexion of the ankles, flexion and extension of the knees and adduction and abduction of the hips, in both lower limbs. All exercises were performed with the patient in the supine position in the bed, in 10 repetitions.
Study NCT00170950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benazepril/amlodipine 40/5 mg - Dose Level 2 from Month 1 to Month 2
Description: Benazepril hydrochloride (HCl)/amlodipine besylate 20/5 mg capsules for oral administration once daily.
Study NCT00170950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benazepril/amlodipine 40/10 mg - Dose Level 3 from Month 2 to Month 3 and thereafter
Description: Benazepril hydrochloride (HCl)/amlodipine besylate: 40/10 mg capsules for oral administration once daily. Patients titrated to this dose level had the possibility of subsequent free add-on antihypertensive agents after month 3 based on target blood pressure.
Study NCT03392311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcipotriol ointment
Description: The topical treatment in the study was calcipotriol ointment(Dovonex;LEO Laboratories Ltd, Ireland) twice daily for 12 weeks.
Study NCT03392311 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: adipose-derived multipotent mesenchymal stem cells
Description: AD-MSCs(adipose-derived multipotent mesenchymal stem cells) were infused intravenously at a dose of 2 million cells/kg.
Study NCT01221597 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AA4500
Description: 2 injections separated by at least 24 hours but not more than 72 hours. At least 24 hours but not more than 72 hours after the 2nd injection of the treatment cycle, the investigator will model the plaque (ie, gradual, gentle stretching of the flaccid penis in the direction opposite to the curvature). Treatment may be repeated after 42 days (± 5 days) for up to 4 treatment cycles.
Study NCT00170950 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Benazepril/hydrochlorothiazide 20/12.5 mg - Dose Level 1 from Day 1 to Month 1
Description: Benazepril hydrochloride (HCl)/hydrochlorothiazide (HCTZ) 20/12.5 mg capsules for oral administration once daily.
Study NCT00170950 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Benazepril/hydrochlorothiazide 40/12.5 mg - Dose Level 2 from Month 1 to Month 2
Description: Benazepril hydrochloride (HCl)/hydrochlorothiazide (HCTZ) 40/12.5 mg capsules for oral administration once daily.
Study NCT00170950 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Benazepril/hydrochlorothiazide 40/25 mg - Dose Level 3 from Month 2 to Month 3 and thereafter
Description: Benazepril hydrochloride (HCl)/hydrochlorothiazide (HCTZ) 40/25 mg capsules for oral administration once daily. Patients titrated to this dose level had the possibility of subsequent free add-on antihypertensive agents after month 3 based on target blood pressure.
Study NCT01221597 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 injections separated by at least 24 hours but not more than 72 hours. At least 24 hours but not more than 72 hours after the 2nd injection of the treatment cycle, the investigator will model the plaque (ie, gradual, gentle stretching of the flaccid penis in the direction opposite to the curvature). Treatment may be repeated after 42 days (± 5 days) for up to 4 treatment cycles.
Study NCT06264050 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: evalutaion scales
Description: four scales will be administered to whom attend a psychological support group: BDI II (depression); Stai Y2 (trait anxiety); Cope NVI 25 (coping strategies) and Core OM (psychological state)
Study NCT04439422 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Short ADHD Intervention
Description: Short, intensive psychological intervention based on CBT and DBT practices
Study NCT04439422 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Self-help material with limited therapist support
Description: Self-help material from an evidence-based treatment manual for adult ADHD with access to limited therapist support via Internet (control group)
Study NCT01479920 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoxetine
Description: Subjects of both study arms received orally administered SSRIs for 4 weeks in an open manner. For those who were currently under antidepressant treatment, they would continue the existing treatment regimens. For those who were not medicated at the time of trial, fluoxetine (FLX) was given at an initiate dose of 10 mg/day and escalated to an optimal dose within one week, based on individual response, but the maximum dose was set at 40 mg/day.
Study NCT01479920 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Fluoxetine
Description: Subjects of both study arms received orally administered SSRIs for 4 weeks in an open manner. For those who were currently under antidepressant treatment, they would continue the existing treatment regimens. For those who were not medicated at the time of trial, fluoxetine (FLX) was given at an initiate dose of 10 mg/day and escalated to an optimal dose within one week, based on individual response, but the maximum dose was set at 40 mg/day.
Study NCT01479920 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: DCEAS (Hwato®/ Dongbang®)
Description: Six pairs of cranial acupoints are used: Baihui (Du-20) and Yintang (EX-HN3), left Sishencong (EX-HN1) and Toulinqi (GB15), right Sishencong (EX-HN1) and Toulinqi (GB15), bilateral Shuaigu (GB8), bilateral Taiyang (EX-HN5), and bilateral Touwei (ST8). All these acupoints are located on the forehead.~Disposable acupuncture needles (Hwato®/ Dongbang®, 0.30 mm in diameter and 25-40 mm in length) are inserted at a depth of 10-30 mm obliquely into acupoints, on which low- and high-frequency alternating electrical stimulation with continuous waves is conducted for 30 min. The intensity is adjusted to a level at which patients feel comfortable.
Study NCT01479920 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: n-CEA (Strietberger®)
Description: Streitberger's acupuncture needles will be applied on the same acupoints, with the same electrical stimulation parameters, except that the needles only adhere to the skin instead of insertion.
Study NCT02127164 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Veraflo device, Dakin's solution
Description: Veraflo device will be installed on the wound to create negative pressure after surgery. Dakin's solution will be instilled through this device into the wound at the regular intervals.
Study NCT03643952 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daptomycin for Injection
Description: Once daily administration of 5, 7, 9, 10, or 12 mg/kg intravenous (IV) daptomycin infused with 25-50 mL saline over 30-60 minutes depending upon infection type and age level.
Study NCT01598480 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flamazine
Description: Silver sulfadiazine cream
Study NCT01598480 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BCT Antimicrobial Dressing
Description: Activated carbon fiber impregnated with silver particles
Study NCT03942250 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: REGE pro dressing
Description: REGE pro is a dressing of dried human amniotic membrane sterilized by gamma radiation
Study NCT04134442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine Liposome Injection
Description: 1. Standard pre-operative and post-operative medical regimen including standing acetaminophen 650mg q6hours, gabapentin 300mg q8hours and as needed oxycodone every 4 hours (unless there are contraindications due to liver function, kidney function, age, or current therapy as currently determined by APS anesthesiologist)~2. Pre-operative ultrasound guided ISNB with a 20ml mixture consisting of 10ml of 0.5% bupivacaine with epinephrine 1:200,000, and 10ml of BL 1.33%
Study NCT04134442 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Therapy
Description: 1. Standard pre-operative and post-operative medical regimen including standing acetaminophen 650mg q6hours, gabapentin 300mg q8hours and as needed oxycodone every 4 hours (unless there are contraindications due to liver function, kidney function, or age as currently determined by acute pain service (APS) anesthesiologist)~2. Preoperative, ultrasound guided ISNB with a bupivacaine mixture: 20ml 0.5% bupivacaine and epinephrine 1:200,000.
Study NCT02939404 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold exposure
Description: 23.25 hours inside respiratory chamber with the temperature set to19°C
Study NCT02939404 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Normal temperature
Description: 23.25 hours inside respiratory chamber with the temperature set to 24°C
Study NCT02939404 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fixed diet
Description: A diet that matches the participant's caloric needs
Study NCT02939404 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ad libitum diet
Description: Participants can eat as much as they want
Study NCT02939404 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fasting
Description: Participants do not eat for 12 hours before and 24 hours in chamber
Study NCT02500992 — intervention group
Intervention type: PROCEDURE
Intervention: Transrectal sigmoidectomy
Study NCT03455972 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-CD19 and anti-BCMA CAR
Description: Participants will get auto-HSCT. Hematopoietic reconstitution after auto-HSCT, participants will get the anti-CD19 CAR T cells (1×10e+7/kg on d0) and anti-BCMA CAR T cells as split-dose (total 5×10e+7/kg, 40% on d1 and 60% on d2)
Study NCT03455972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immunomodulatory drugs
Description: Maintenance therapy
Study NCT03579459 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Clostridium difficile vaccine
Description: Toxoid based Clostridium difficile vaccine
Study NCT03579459 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Normal saline solution